Peer-influenced content. Sources you trust. No registration required. This is HCN.

Sotrovimab No Longer Authorized to Treat COVID-19 in Areas with High BA.2 Frequency

The FDA has withdrawn its authorization for use of the monoclonal antibody sotrovimab in the treatment of COVID-19 in regions with a high frequency of the Omicron BA.2 subvariant. Data show that the authorized dose of the monoclonal antibody — 500 mg — is unlikely to be effective against the BA.2 COVID-19 subvariant.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form